CNDP2 and tuberculosis: Among the candidate vaccines, M72/AS01E—a subunit vaccine comprising a fusion protein of M. tuberculosis antigens (PepA and PPE18) and the AS01E adjuvant system—has demonstrated 49.7% efficacy in preventing active TB in latently infected adults [10].